about
Molecular basis of the γ-aminobutyric acid A receptor α3 subunit interaction with the clustering protein gephyrinEndocannabinoids modulate cortical development by configuring Slit2/Robo1 signallingDevelopmental patterns of DR6 in normal human hippocampus and in Down syndromeAging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy.Linking pathways in the developing and aging brain with neurodegeneration.Validation of dopamine receptor DRD1 and DRD2 antibodies using receptor deficient mice.The physiological phosphorylation of tau is critically changed in fetal brains of individuals with Down syndrome.Spatio-temporal expression analysis of the calcium-binding protein calumenin in the rodent brainIncidental corticobasal degeneration in a 76-year-old woman.Non-neuronal cell responses differ between normal and Down syndrome developing brains.Patterns of hippocampal tau pathology differentiate neurodegenerative dementias.GABAA receptor subunits in the human amygdala and hippocampus: Immunohistochemical distribution of 7 subunits.Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.GABAA receptor subunit deregulation in the hippocampus of human foetuses with Down syndrome.Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series.Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease.Patterns of Tau and α-Synuclein Pathology in the Visual System.Shared and Distinct Patterns of Oligodendroglial Response in α-Synucleinopathies and Tauopathies.Initial diagnosis of the congenital disorder of glycosylation PMM2-CDG (CDG1a) in a 4-year-old girl after neurosurgical intervention for cerebral hemorrhage.I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.Metabotropic glutamate receptor 5 in Down's syndrome hippocampus during development: increased expression in astrocytes.mTOR Hyperactivation in down syndrome hippocampus appears early during development.The parvalbumin-positive interneurons in the mouse dentate gyrus express GABAA receptor subunits α1, β2, and δ along their extrasynaptic cell membrane.Sustained consumption of cocoa-based dark chocolate enhances seizure-like events in the mouse hippocampus.The α1, α2, α3, and γ2 subunits of GABAA receptors show characteristic spatial and temporal expression patterns in rhombencephalic structures during normal human brain development.Hippocampal Radial Glial Subtypes and Their Neurogenic Potential in Human Fetuses and Healthy and Alzheimer's Disease Adults.Distinct patterns of sirtuin expression during progression of Alzheimer's disease.The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.Structural and Functional Remodeling of Amygdala GABAergic Synapses in Associative Fear LearningRapid antidepressant effect of S-ketamine in schizophreniaSlowed vertical saccades as a hallmark of hereditary spastic paraplegia type 7Alterations in GABAA Receptor Subunit Expression in the Amygdala and Entorhinal Cortex in Human Temporal Lobe EpilepsyA novel nonsense autosomal dominant mutation in the GLRA1 gene causing hyperekplexiaAdult-onset variant ataxia-telangiectasia diagnosed by exome and cDNA sequencingGenotype-guided diagnostic reassessment after exome sequencing in neuromuscular disorders: experiences with a two-step approach
P50
Q28574183-123C11A2-632D-4FA2-BBCF-1259986F56F5Q33948817-2D1165F0-3876-4988-B03A-2FEF4D2EC896Q36884903-0E69793D-D6E7-4756-BA46-14CF12BBA96BQ36932383-A3F9493A-F041-4B0D-A83D-19512D279117Q38201983-8A6E3E0A-EF95-44BA-BADA-2D46B6453E16Q38743208-1DA6AEFA-347E-4A9B-8BE7-64D9F5D64E8AQ38813201-E5B529A2-2737-4920-B08C-7E576918B57BQ40786201-7B50D361-1D19-4994-8ED1-7A89C3326C66Q44310566-4BC23851-5761-4869-A327-062306815038Q44544059-568DF99F-BB57-4DD3-A0CE-92E0660983FFQ45015804-7D852E73-0E83-4866-A70E-E893195B4D70Q46288122-2870E8CA-E7D1-46F2-AFE0-E90EEB436116Q46467299-71D7D31B-E2AF-41BC-9E9A-87363A814A2AQ47371832-FE2608B0-0612-4FA5-ABAD-9C8E0D449766Q47896160-08E1808F-4E01-449C-940C-F67128A29653Q48190344-F78EAA0A-6D28-4C47-A589-8878669BD28BQ48298552-21B20F8D-F08A-4A71-9867-C0FEB6D0D04BQ48494051-3363F1D7-5132-4EAD-A01D-222E0DE251E8Q48562694-44E62ED0-BDDD-4D63-94CC-6F99C45B1A7FQ48568104-F9F660AA-32CA-494F-8475-E4FFDB2C9BF1Q48609005-65E0B350-502C-473F-BF95-4C0AD8A015F1Q48721008-A7A2A290-EA98-43B2-B2E4-9A4EB41333DAQ48986730-51FB6499-352C-4960-8CB2-7B1F9F7F0C14Q50065676-B1F238CE-8D0C-4AF7-B190-8B94B4309145Q50552053-2CE6D356-B9C3-4194-BB8E-ACB97A403D5CQ52714208-A29246BA-A581-44C1-A70D-E9FF5E61F530Q53348494-8A393F9A-05F1-42F5-8624-AEA0CCA75541Q55265334-928468B4-F6A1-44AD-AA0A-F8DBB374429DQ90204736-7081A594-7E98-4F10-9D30-D2A410FDB6B7Q90449909-36E735BE-298E-46DF-8055-7CA6B5FD78C2Q90647484-9ABB3016-3E66-454E-8FC6-2FFB8CFC4CFFQ90830038-BE5624BE-8626-4480-8F5D-58413B870256Q91291729-AF7748CC-C519-4CE4-A508-A4668E83FA52Q92557964-6A25F232-727A-4443-AC27-CBC35E9FEC64Q92586260-F7FE5AFE-4E7B-4A85-8373-12FFFBA8B322
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ivan Milenkovic
@ast
Ivan Milenkovic
@en
Ivan Milenkovic
@es
Ivan Milenkovic
@nl
type
label
Ivan Milenkovic
@ast
Ivan Milenkovic
@en
Ivan Milenkovic
@es
Ivan Milenkovic
@nl
prefLabel
Ivan Milenkovic
@ast
Ivan Milenkovic
@en
Ivan Milenkovic
@es
Ivan Milenkovic
@nl
P106
P21
P31
P496
0000-0002-2990-0243